Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRVO NASDAQ:FLGC NASDAQ:PYRGF NASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVOCervoMed$7.41-2.1%$7.39$1.80▼$20.63$64.49M-0.751.35 million shs67,292 shsFLGCFlora Growth$0.62-1.7%$0.67$0.42▼$2.11$14M1.97275,798 shs173,172 shsPYRGFPyroGenesis Canada$0.32+1.5%$0.34$0.30▼$0.71$60.78M0.8411,463 shs7,521 shsUNCYUnicycive Therapeutics$4.43-4.7%$5.94$2.02▼$11.00$56M1.89284,640 shs519,145 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVOCervoMed0.00%+3.64%+6.01%-24.39%-59.82%FLGCFlora Growth0.00%-9.49%-13.65%+15.13%-43.64%PYRGFPyroGenesis Canada0.00%-2.96%-6.81%+1.72%-50.91%UNCYUnicycive Therapeutics0.00%-11.58%-33.63%-26.20%+0.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRVOCervoMed2.7802 of 5 stars3.45.00.00.00.61.70.6FLGCFlora Growth1.7214 of 5 stars3.33.00.00.00.60.80.6PYRGFPyroGenesis Canada0.1132 of 5 stars0.02.00.00.00.01.70.0UNCYUnicycive Therapeutics2.5199 of 5 stars3.74.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRVOCervoMed 2.89Moderate Buy$22.57204.61% UpsideFLGCFlora Growth 2.50Moderate Buy$4.00545.16% UpsidePYRGFPyroGenesis Canada 0.00N/AN/AN/AUNCYUnicycive Therapeutics 3.33Buy$60.001,254.40% UpsideCurrent Analyst Ratings BreakdownLatest FLGC, CRVO, PYRGF, and UNCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/27/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$90.005/13/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/12/2025CRVOCervoMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $15.004/21/2025UNCYUnicycive TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRVOCervoMed$9.74M6.62N/AN/A$4.50 per share1.65FLGCFlora Growth$59.51M0.24N/AN/A$0.31 per share2.00PYRGFPyroGenesis Canada$9.14M6.65N/AN/A($0.01) per share-32.45UNCYUnicycive Therapeutics$680K82.35N/AN/A$0.72 per share6.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRVOCervoMed-$16.29M-$2.18N/AN/AN/A-200.57%-44.07%-40.65%8/8/2025 (Estimated)FLGCFlora Growth-$15.91M-$0.98N/AN/AN/A-24.85%-216.49%-45.56%8/11/2025 (Estimated)PYRGFPyroGenesis Canada-$21.12M-$0.02N/A∞N/A-115.14%N/A-60.81%N/AUNCYUnicycive Therapeutics-$36.73M-$5.10N/AN/AN/AN/A-277.30%-61.53%N/ALatest FLGC, CRVO, PYRGF, and UNCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025FLGCFlora Growth-$0.06N/AN/AN/A$11.77 millionN/A8/8/2025Q2 2025CRVOCervoMed-$0.55N/AN/AN/A$1.45 millionN/A5/14/2025Q1 2025UNCYUnicycive Therapeutics-$1.40-$0.50+$0.90-$0.05N/AN/A5/13/2025Q1 2025FLGCFlora Growth-$0.01-$0.04-$0.03-$0.04$14.79 million$11.79 million5/12/2025Q1 2025CRVOCervoMed-$0.60-$0.56+$0.04-$0.56$1.70 million$1.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRVOCervoMedN/AN/AN/AN/AN/AFLGCFlora GrowthN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRVOCervoMedN/A9.789.78FLGCFlora Growth0.881.050.67PYRGFPyroGenesis CanadaN/A0.600.50UNCYUnicycive TherapeuticsN/A1.641.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRVOCervoMed25.15%FLGCFlora Growth36.01%PYRGFPyroGenesis Canada0.03%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipCRVOCervoMed35.40%FLGCFlora Growth12.56%PYRGFPyroGenesis Canada47.68%UNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRVOCervoMed48.70 million5.62 millionNot OptionableFLGCFlora Growth28022.57 million19.73 millionNot OptionablePYRGFPyroGenesis Canada90187.31 million96.34 millionNo DataUNCYUnicycive Therapeutics912.64 million11.29 millionNot OptionableFLGC, CRVO, PYRGF, and UNCY HeadlinesRecent News About These CompaniesUNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. ...July 19 at 3:23 PM | gurufocus.comUNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law FirmJuly 19 at 2:19 PM | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 17 at 10:00 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 14, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 12, 2025 | prnewswire.comUnicycive Therapeutics, Inc.: Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 8, 2025 | finanznachrichten.deUnicycive Therapeutics Regains Compliance with Nasdaq Listing Standards Following Share Price RecoveryJuly 8, 2025 | quiverquant.comQUnicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 8, 2025 | globenewswire.comUnicycive Therapeutics (NASDAQ:UNCY) Trading 2% Higher - Time to Buy?July 8, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 7, 2025 | prnewswire.comUnicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual ConferenceJuly 7, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY - MorningstarJuly 3, 2025 | morningstar.comMINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 2, 2025 | prnewswire.comUnicycive hit with CRL on oxylanthanum carbonate NDAJuly 1, 2025 | thepharmaletter.comTKaplan Fox & Kilsheimer LLP is Investigating Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law ViolationsJuly 1, 2025 | theglobeandmail.comUnicycive Therapeutics, Inc. (UNCY) - Yahoo FinanceJune 30, 2025 | finance.yahoo.comFDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospectJune 30, 2025 | fiercepharma.comFUnicycive receives CRL for oxylanthanum carbonate NDA for hyperphosphatemiaJune 30, 2025 | msn.comUnicycive stock falls after FDA issues Complete Response LetterJune 30, 2025 | investing.comUnicycive Shares Slide Premarket as FDA Rejects Oxylanthanum Carbonate ApplicationJune 30, 2025 | marketwatch.comUnicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease ...June 30, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFLGC, CRVO, PYRGF, and UNCY Company DescriptionsCervoMed NASDAQ:CRVO$7.41 -0.16 (-2.11%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$7.42 +0.00 (+0.07%) As of 07/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Flora Growth NASDAQ:FLGC$0.62 -0.01 (-1.74%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.64 +0.02 (+3.71%) As of 07/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.PyroGenesis Canada NASDAQ:PYRGF$0.32 +0.00 (+1.50%) As of 07/18/2025 03:47 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.Unicycive Therapeutics NASDAQ:UNCY$4.43 -0.22 (-4.73%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$4.58 +0.15 (+3.39%) As of 07/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
